Voyager Therapeutics reported a significant increase in quarterly collaboration revenue and maintained a strong cash position of $201.7 million, which is expected to fund operations into 2028. While the company realized a net loss for the quarter, it was narrower than the previous year's Q4, and the company is preparing for multiple clinical entries in the second half of 2026.
Collaboration revenue for Q4 increased to $15.3 million, up from $6.3 million in the prior year period, driven by the Neurocrine agreement.
Cash runway is projected to extend into 2028, supported by $201.7 million in cash, cash equivalents, and marketable securities.
Multiple clinical milestones are anticipated in H2 2026, including first-in-human dosing for VY1706 and tau PET imaging data for VY7523.
The company triggered a $3 million milestone payment from Neurocrine in Q4 2025 following the initiation of a preclinical toxicology study.
Voyager expects its current cash position to fund operations into 2028 and anticipates several clinical milestones in 2026.
Analyze how earnings announcements historically affect stock price performance